TY - JOUR T1 - Novel highly divergent SARS-CoV-2 lineage with the Spike substitutions L249S and E484K JF - medRxiv DO - 10.1101/2021.03.12.21253000 SP - 2021.03.12.21253000 AU - Katherine Laiton-Donato AU - Jose A. Usme-Ciro AU - Carlos Franco-Muñoz AU - Diego A. Álvarez-Díaz AU - Hector Alejandro Ruiz-Moreno AU - Jhonnatan Reales-González AU - Diego Andrés Prada AU - Sheryll Corchuelo AU - Maria T. Herrera-Sepúlveda AU - Julian Naizaque AU - Gerardo Santamaría AU - Magdalena Wiesner AU - Diana Marcela Walteros AU - Martha Lucia Ospina Martínez AU - Marcela Mercado-Reyes Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/15/2021.03.12.21253000.abstract N2 - COVID-19 pandemics has led to genetic diversification of SARS-CoV-2 and the appearance of variants with potential impact in transmissibility and viral escape from acquired immunity. We report a new lineage containing ten distinctive amino acid changes across the genome. Further studies are required for monitoring its epidemiologic impact.Competing Interest StatementThe authors have declared no competing interest.Funding StatementI include a the availability of all data referred to in the manuscript and web links.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The INS is the reference lab and health authority of the national network of laboratories. In case of a public health emergency or when scientific research in public health is required, the national law 9/1979, decrees 786/1990 and 2323/2006, authorizes the INS to use the biological material and associated epidemiological information without informed consent, including the anonymous disclosure of results. This study was approved in the project CEMIN-4-2020 by the Ethical commit of the Instituto Nacional de Salud Colombia and performed following the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments. The information used for this study comes from secondary sources of data that were anonymized and do not represent a risk to the community.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors approved availability of all data referred to in the manuscript and web links. ER -